Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that β-catenin overexpression in human squamous cell carcinoma cells led to increased CREB expression, which significantly enhanced clonogenic activity, suggesting CREB as a β-catenin-regulated factor promoting cancer characteristics.

This study found that ERBB2 mutations and amplifications are likely key drivers of extramammary Paget disease, suggesting potential for targeted therapies and cancer immunotherapy due to the moderately high mutational load observed.

In a clinical phase I/IIa study, subcutaneous injections of the peptide FOL-005 increased hair growth by 8% and were safe for treating alopecia.

This chapter reviews the skin side effects associated with targeted cancer therapies and emphasizes the importance of collaboration between oncologists and dermatologists without reporting new results.

This chapter reviews disorders of skin appendages including miliaria, acne, and alopecia, providing guidance on management and treatment but does not present new clinical findings.

This review discusses frontal fibrosing alopecia and reports no new clinical results; the authors highlight the need for randomized controlled trials on 5AR inhibitors to assess their efficacy and safety.

This review reported that 5-alpha-reductase inhibitors were effective in stabilizing disease progression or reducing the rate of progression in some cases of frontal fibrosing alopecia, though evidence on safety remains limited.

This case report describes a patient with frontal fibrosing alopecia experiencing significant hair regrowth and reversal of cutaneous atrophy after treatment with the 5α-reductase inhibitor finasteride.

This editorial response discusses the evidence for using 5-alpha reductase inhibitors in treating frontal fibrosing alopecia, acknowledging its potential benefits while emphasizing the need for further studies to establish it as a standard treatment.

This study reported that certain newly synthesized steroidal derivatives showed stronger inhibitory activity against the 5α-reductase enzyme than finasteride in hamsters, suggesting their potential as enzyme inhibitors.

This study found that novel RNA aptamers specifically inhibited FGF5-induced cell proliferation, suggesting their potential as candidates for treating FGF5-related diseases or hair disorders.

This study found that after 12 months of treatment with 5 mg of finasteride, patients with benign prostatic hyperplasia showed reduced prostate volume, DHT and PSA levels, and improved urinary flow rates and symptoms.

This article reviews the use of 5α-reductase inhibitors for treating benign prostatic hyperplasia, suggesting potential benefits beyond symptom relief, but it reports no new clinical results.

This study concluded that the market for 5α-reductase inhibitors, including finasteride, epristeride, and dutasteride, is expected to grow with promising prospects.

This review discusses finasteride's use in manipulating neuroactive steroid levels and its potential effects on behavior, reporting preclinical evidence and clinical observations but providing no new experimental results.

This study found that FGF5 alternative spliceosomes inhibit dermal papilla cell proliferation and regulate hair follicle growth-related gene expression, impacting hair follicle development in rabbits.

This review discusses FAERS data on 5-alpha reductase inhibitors and their potential implications for post-finasteride syndrome, but it does not report any new clinical results.

In a laboratory setting, this study found that overexpression of the FGF5 short form in cultured keratinocytes increased hepatic growth factor gene expression, suggesting a potential role in hair growth.

This study found that 5-aminolevulinic acid combined with ferric ammonium citrate stimulated hair follicle growth and induced hair-like structures in human hair follicle models, suggesting its potential as a treatment for hair loss.

This review discusses the potential role of FGF5 as a therapeutic target in prostate cancer and other conditions but reports no new results, highlighting a need for further research on FGF5 inhibitors.

This study demonstrated that FGF5s acts as an inhibitor of FGF5 in regulating hair growth cycles in cashmere goat dermal papilla cells.

This study found that among eleven tested polymethoxyflavones, 5-hydroxy-7,4′-dimethoxyflavone was the strongest steroid 5α-reductase inhibitor and suggests potential use for benign prostatic hyperplasia treatment.

This study found that pubic skin fibroblasts respond to androgens, increasing 5α-reductase activity via an androgen receptor-mediated mechanism, suggesting its potential as a marker of androgen action in vitro.

This review provides an up-to-date analysis of the efficacy and safety of five-alpha reductase inhibitors, specifically finasteride and dutasteride, for treating benign prostatic hyperplasia and male androgenetic alopecia, highlighting their FDA approval history and current use.

This review compiles existing data on frontal fibrosing alopecia and highlights the promise of 5-alpha reductase inhibitors as a treatment option, while noting the need for clarity on its cause and progression.

In this study, a topical formulation with compounds from the monoterpenoid family significantly improved hair growth indicators like anagen:telogen ratio, hair fall, and visual hair density in men and women with pattern hair loss.

This study found that a newly developed peptide, FOL-005, significantly inhibited hair growth and counteracted minoxidil's effects in organ-cultured human male scalp skin and mouse models, without apparent toxicity.

This review highlights current treatment options for frontal fibrosing alopecia, noting that 5-α-reductase inhibitors, intralesional steroids, and hydroxychloroquine have the highest evidence of effectiveness, while other therapies show variable results and need further research.

This review analyzed the use of 5-alpha reductase inhibitors (5ARIs) for treating various dermatological conditions such as androgenetic alopecia, acne, and hirsutism, emphasizing their efficacy and safety profile.